| Zacks Company Profile for Immune Pharmaceuticals Inc. (IMNPQ : OTC) |
|
|
| |
| • Company Description |
| Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporin, which is in late stage preclinical development for atopic dermatitis and psoriasis.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,963 shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: 1.52 |
| 52 Week High: $0.01 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-37.50% |
-31.52% |
| 12 Week |
-37.50% |
-32.19% |
| Year To Date |
-23.08% |
-8.53% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Elliot M. Maza - President; Chief Executive Officerand Director
Daniel Kazado - Director
Dr. Cameron Durrant - Director
Dr. Daniel G. Teper - Director
John A. Neczesny - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45254C200
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 4.00 (0.05:1)
Beta: 1.52
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
